Orient Europharma Co Stock Probability Of Bankruptcy
4120 Stock | TWD 41.95 0.30 0.71% |
Orient |
Orient Probability Of Bankruptcy Analysis
Orient Europharma's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Orient Europharma Probability Of Bankruptcy | Over 64% |
Most of Orient Europharma's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Orient Europharma Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Orient Europharma probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Orient Europharma odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Orient Europharma Co financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
CompetitionBased on the latest financial disclosure, Orient Europharma Co has a Probability Of Bankruptcy of 64%. This is 47.84% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers-Specialty & Generic industry. The probability of bankruptcy for all Taiwan stocks is 60.68% lower than that of the firm.
Orient Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Orient Europharma's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Orient Europharma could also be used in its relative valuation, which is a method of valuing Orient Europharma by comparing valuation metrics of similar companies.Orient Europharma is currently under evaluation in probability of bankruptcy category among related companies.
Orient Fundamentals
Return On Equity | -0.0268 | |||
Return On Asset | -0.0027 | |||
Profit Margin | (0.02) % | |||
Operating Margin | (0.01) % | |||
Current Valuation | 5.9 B | |||
Shares Outstanding | 86.75 M | |||
Shares Owned By Insiders | 65.10 % | |||
Shares Owned By Institutions | 0.45 % | |||
Price To Book | 1.07 X | |||
Price To Sales | 0.68 X | |||
Revenue | 4.77 B | |||
Gross Profit | 2.15 B | |||
EBITDA | 313.89 M | |||
Net Income | 120.17 M | |||
Total Debt | 1.68 B | |||
Book Value Per Share | 33.54 X | |||
Cash Flow From Operations | 77.65 M | |||
Earnings Per Share | 0.54 X | |||
Number Of Employees | 21 | |||
Beta | 0.4 | |||
Market Capitalization | 3.13 B | |||
Total Asset | 9.4 B | |||
Z Score | 0.6 | |||
Annual Yield | 0.02 % | |||
Net Asset | 9.4 B | |||
Last Dividend Paid | 0.85 |
About Orient Europharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Orient Europharma Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Orient Europharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Orient Europharma Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Orient Stock analysis
When running Orient Europharma's price analysis, check to measure Orient Europharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orient Europharma is operating at the current time. Most of Orient Europharma's value examination focuses on studying past and present price action to predict the probability of Orient Europharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orient Europharma's price. Additionally, you may evaluate how the addition of Orient Europharma to your portfolios can decrease your overall portfolio volatility.
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |